Please let me invite you to contribute to the preparation and later to favour a mindful lecture of this speciel issue of the Journal of Men’s Health dedicated to metastatic prostate cancer.
Although being a leading cause of cancer death, metastatic prostate cancer, compared to other cancer types, is any longer necesserily a life threatening condition. Thanks to recent pharmaceutical developments, several lines of anti-hormonal and cytostatic treatments may provide long years of disease control.
We would like to focus in this special issue to the diagnostic challenges, to the proper use of innovative therapies and to the patients’ perspectives open with the improved prognosis. Differentiating between localised and generalised disease remains problematic even with the best imaging techniques. Sequencing and maintenance of novel drugs are being debated. The men’s own evaluation of the quality of their prolonged life is maybe not enough taken into account.
This special issue offers an opportunity to address the following but other topics:
- Diagnosis and treatment of oligometastatic disease
- Diagnosis and treatment of micrometastatic disease
- Diagnosis and treatment of neuroendocrin cancer of the prostate
- Optimal selection of systemic therapies
- Optimal maintenance of second line antiandrogenic therapies
- Optimal comedication of androgen synthesis inhibitors
- Optimal dosing of bisphosphonates
- Quality of life of patients with metastatic prostate cancer
Let’s share our experience to the better care of the patients of all of us.
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted manuscripts should be well formatted in good English.
- Complementary Elements to the Pathogenesis, Early Detection and Second Line Antihormonal Therapy of Prostate CancerTamás KullmannJ. Mens. Health 2022, 18(7), 155; https://doi.org/10.31083/j.jomh180715510Download81Views
- Prostatic signet-ring adenocarcinoma: A case reportAli Al Khader, Esra Nsour, Taleb Al EdwanJ. Mens. Health 2022, 18(4), 90; https://doi.org/10.31083/j.jomh180409021Download74Views
- Optimisation of second line antihormonal treatment for castration resistant metastatic prostate cancerKullmann Tamás, Kocsis Károly, Ambrus Adél, Kránitz Noémi, ... Szepesváry ZsoltJ. Mens. Health 2022, 18(4), 93; https://doi.org/10.31083/j.jomh180409314Download45Views
- Neuroendocrine cancer of the prostate. Two case reportsTamás Kullmann, Szigeti András, Kránitz Noémi, Szepesváry ZsoltJ. Mens. Health 2022, 18(3), 65; https://doi.org/10.31083/j.jomh180306523Download57Views
- A single centre pilot experience with 18F-JK-PSMA-7 PET-CT in the staging of prostate cancerSzigeti András, Kocsis Károly, Ambrus Adél, Kránitz Noémi, ... Kullmann TamásJ. Mens. Health 2022, 18(2), 45; https://doi.org/10.31083/jomh.2021.13316Download56Views
- The diagnostic value of a new formula combining age and prostate volume in prostate cancerXiaobo Yang, Jiahao Shan, Qiang Zhang, Zhongyu Yuan, ... Hongbin ShiJ. Mens. Health 2022, 18(2), 29; https://doi.org/10.31083/jomh.2021.08016Download68Views
- The 100 most-cited articles in castration-resistant prostate cancer: a bibliometric analysisHui Fang, Lugeng He, Huadong He, Xuliang Wang, ... Chao ChenJ. Mens. Health 2022, 18(1), 3; https://doi.org/10.31083/jomh.2021.05317Download93Views
- Insights into association between urolithiasis and prostate cancerXiaolu Sun, Bhuman Deep Kour, Xiangtao Wang, Xiufang Hu, ... Vuree SugunakarJ. Mens. Health 2021, 17(4), 52–61; https://doi.org/10.31083/jomh.2021.07025Download79Views
- Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening programMarquita W. Lewis-Thames, Saira Khan, Veronica Hicks, Bettina F. DrakeJ. Mens. Health 2021, 17(4), 78–83; https://doi.org/10.31083/jomh.2021.08130Download118Views
- Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (75) patientsAli Alkan, Zeynep Gülsüm Güç, Mustafa Gürbüz, Güliz Özgün, ... Yüksel ÜrünJ. Mens. Health 2021, 17(4), 128–134; https://doi.org/10.31083/jomh.2021.04125Download83Views
- Decrease in prostate cancer detection during COVID-19 pandemicDaniel Porav-Hodade, Daniel Balan, Raul Gherasim, Oliver Arpad Vida, ... Orsolya MarthaJ. Mens. Health 2021, 17(4), 151–155; https://doi.org/10.31083/jomh.2021.11014Download50Views
- A comprehensive mechanistic basis of prostate cancer advancement & its personalized implementation-bridging the gap: present state and future prospectDipamoy Datta, Md Aftabuddin, Raja Kundu, Mayank Baid, ... Leena KumariJ. Mens. Health 2021, 17(3), 18–35; https://doi.org/10.31083/jomh.2021.02917Download72Views